Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts
International Journal of Laboratory Hematology · 2023
DOI: 10.1111/ijlh.14030 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Laboratory Hematology, 2023. Verfasst von Kai Shen und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Soo…. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Gefördert von: the Innovation Capability Development Project of Jiangsu Province, the National Key R&D Program of China, the Translational Research Grant of NCRCH.
Abstract (Originalsprache)
Introduction
Myeloid tumors typically harbor TP53 mutations, which are linked to a dismal prognosis. There are fewer studies on whether TP53‐mutated acute myeloid leukemia (AML) and myelodysplastic syndrome with excess blasts (MDS‐EB) differ in molecular characteristics and should be considered as separate entities.
Methods
Between January 2016 and December 2021, a retrospective analysis was done on a total of 73 newly diagnosed AML patients and 61 MDS‐EB patients from the first affiliated hospital of Soochow University. We described a survival profile and a thorough characterization of newly found TP53‐mutant AML and MDS‐EB and investigated the relationship between these characteristics and overall survival (OS).
Results
38 (31.1%) were mono‐allelic, and 84 (68.9%) were bi‐allelic. There is no significant difference between TP53‐mutated AML and MDS‐EB (median OS 12.9 verse 14.4 months; p = .558). Better overall survival was linked to mono‐allelic TP53 than bi‐allelic TP53(HR = 3.030, CI:1.714–5.354, p < .001). However, the number of TP53 mutations and comutations were not significantly associated with OS. TP53 variant allele frequency cutoff of 50% is significant correlation with OS (HR: 2.177, 95% CI: 1.142–4.148; p = .0063).
Conclusion
Our data revealed that allele status and allogeneic hematopoietic stem cell transplant independently affect the prognostic of AML and MDS‐EB patients, with a concordance of molecular features and survival between these two disease entities. Our analysis favors considering TP53‐mutated AML/MDS‐EB as a distinct disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, People's Republic of China.
- Institute of Blood and Marrow Transplantation, Soochow University, Suzhou, People's Republic of China.
ORCID-Profile: Kai Shen, De-Yuan Hu
Förderung
- the Innovation Capability Development Project of Jiangsu Province
- the National Key R&D Program of China
- the Translational Research Grant of NCRCH
Zitieren
APA
Shen, K., Hu, D. Y., Zhang, Z. B., Guo, Y. S., Zhang, F. H., & Chen, S. N. (2023). Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts. International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.14030
Vancouver
Shen K, Hu DY, Zhang ZB, Guo YS, Zhang FH, Chen SN. Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts. International Journal of Laboratory Hematology. 2023. doi:10.1111/ijlh.14030
BibTeX
@article{Shen2023,
author = {Shen, Kai and Hu, De-Yuan and Zhang, Zhi-Bo and Guo, Yu-Sha and Zhang, Feng-Hong and Chen, Su-Ning},
title = {Molecular characterization and prognosis of mutant TP53 acute myeloid leukemia and myelodysplastic syndrome with excess blasts},
journal = {International Journal of Laboratory Hematology},
year = {2023},
doi = {10.1111/ijlh.14030}
}
EUVIMED